GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » Other Current Assets

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Other Current Assets : $2.64 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Other Current Assets?

Corbus Pharmaceuticals Holdings's other current assets for the quarter that ended in Dec. 2023 was $2.64 Mil.

Corbus Pharmaceuticals Holdings's quarterly other current assets increased from Jun. 2023 ($1.71 Mil) to Sep. 2023 ($2.47 Mil) and increased from Sep. 2023 ($2.47 Mil) to Dec. 2023 ($2.64Mil).

Corbus Pharmaceuticals Holdings's annual other current assets declined from Dec. 2021 ($2.56 Mil) to Dec. 2022 ($0.98 Mil) increased from Dec. 2022 ($0.98 Mil) to Dec. 2023 ($2.64 Mil).


Corbus Pharmaceuticals Holdings Other Current Assets Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Other Current Assets Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.73 4.06 2.56 0.98 2.64

Corbus Pharmaceuticals Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 1.64 1.71 2.47 2.64

Corbus Pharmaceuticals Holdings Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Corbus Pharmaceuticals Holdings Other Current Assets Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Executives
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alan F Holmer director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062

Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Headlines

From GuruFocus